AzTrials
AzTrials

Advanced Parkinson's DiseasePhase 3NCT02549092

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

A Phase 3 study testing Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel and Nasojejunal (NJ) tube in people with Advanced Parkinson's Disease, run by AbbVie at 38 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD. Read more about this study

Who is it for?
Ages 30 years and older
Conditions the study is for
Advanced Parkinson's Disease
What is being tested?
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel and Nasojejunal (NJ) tube
Could I receive a placebo?
No, everyone receives an active treatment
How many people
89 participants
Where
38 sitesin 9 countries
Study dates
26 Oct 2015to 18 Nov 2022
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant(s) must have a diagnosis of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.
  • Participant(s) demonstrates persistent motor fluctuations in spite of individually optimized treatment.
  • The participant's Parkinson's disease is levodopa-responsive.
  • Participant(s) has had optimized treatment with available anti-PD medication and their motor symptoms are judged inadequately controlled on this optimized treatment. Optimized treatment is defined as the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected regardless of any additional manipulations of levodopa and/or other antiparkinsonian medication. This will be based on the Investigator's clinical judgment.
  • Male or female participant(s) must be at least 30 years of age.
  • Minimum Parkinson's Disease Sleep Scale 2 (PDSS-2) total score of 18 at Baseline assessment.

Who cannot join

  • Participant's PD diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body disease) or other neurodegenerative disease that might mimic the symptoms of PD.
  • Participant(s) has undergone neurosurgery for the treatment of Parkinson's disease.
  • Known hypersensitivity to levodopa, carbidopa or radiopaque material.
  • Participant(s) has contraindications to levodopa (e.g. narrow angle glaucoma, malignant melanoma).
  • Participant(s) experiencing clinically significant sleep attacks or clinically significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any point during the three months prior to the Screening evaluation as judged by the Principal Investigator.

Trial locations and contacts

38 sites in 9 countries.

38 sites in 9 countries

Spain9 sites
  • Hospital Clinic de Barcelona /ID# 137689

    Barcelona, 08036

  • Hospital Santa Creu i Sant Pau /ID# 136581

    Barcelona, 08041

  • Hospital Puerta del Mar /ID# 157977

    Cadiz, 11009

  • Hospital Universitario Virgen de las Nieves /ID# 136583

    Granada, 18014

  • Hospital Universitario de Bellvitge /ID# 136579

    L'Hospitalet de Llobregat, Barcelona, 08907

  • CHU Insular-Materno Infantil /ID# 136783

    Las Palmas de Gran Canaria, Las Palmas, 35016

  • Hospital Universitario Ramon y Cajal /ID# 136784

    Madrid, 28034

  • Hospital Universitario Virgen del Rocio /ID# 145624

    Seville, 41013

  • Hospital Universitario y Politecnico La Fe /ID# 136722

    Valencia, 46026

Other trials in Spain

United States8 sites
  • Boca Raton Regional Hospital /ID# 200056

    Boca Raton, Florida, 33486

  • Rush University Medical Center /ID# 168088

    Chicago, Illinois, 60612

  • Parkinson's and Movement /ID# 161596

    Fountain Valley, California, 92708

  • University of Florida Neurolog /ID# 168699

    Jacksonville, Florida, 32209

  • St. Luke's Health System /ID# 168706

    Kansas City, Missouri, 64111

  • Parkinson's Disease Treatment Center of Southwest Florida /ID# 168085

    Port Charlotte, Florida, 33980

  • Central Texas Neurology Consul /ID# 168087

    Round Rock, Texas, 78681

  • Inland Northwest Research /ID# 200113

    Spokane, Washington, 99202-1342

Other trials in United States

Italy7 sites
  • A.O. Univ. Ospedali Riuniti /ID# 135964

    Ancona, The Marches, 60126

  • Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 136789

    Bologna, 40139

  • A.O.U. Ospedali Riuniti di Fog /ID# 136792

    Foggia, 71100

  • A.O.U. Policlinico G. Martino /ID# 136790

    Messina, 98125

  • Ospedale S.Maria della Miseri /ID# 160609

    Perugia, 06132

  • Azienda Sanitaria Locale di /ID# 160608

    Ponderano,biella, 13875

  • Azienda Policlinico Umberto I /ID# 201223

    Roma, 00161

Other trials in Italy

Australia4 sites
  • Royal Adelaide Hospital /ID# 136577

    Adelaide, South Australia, 5000

  • Royal Melbourne Hospital /ID# 136780

    Parkville, Victoria, 3050

  • Goulburn Valley Hospital /ID# 164202

    Shepparton, Victoria, 3630

  • Westmead Hospital /ID# 136575

    Westmead, New South Wales, 2145

Other trials in Australia

Canada3 sites
  • University of Alberta /ID# 136586

    Edmonton, Alberta, T6G 2X8

  • The Ottawa Hospital /ID# 139341

    Ottawa, Ontario, K1H 8L6

  • Toronto Western Hospital /ID# 136585

    Toronto, Ontario, M5T 2S8

Other trials in Canada

South Korea3 sites
  • Severance Hospital /ID# 163019

    Seoul, Seoul Teugbyeolsi, 03722

  • Seoul National University Hospital /ID# 162990

    Seoul, 03080

  • Asan Medical Center /ID# 163018

    Seoul, 05505

Other trials in South Korea

Greece2 sites
  • 251 Airforce General Hospital /ID# 160594

    Athens, Attica, 11525

  • Mediterraneo Hospital /ID# 208042

    Glyfada, 16675

Other trials in Greece

Germany1 site
  • Central Hospital Bremerhaven /ID# 136573

    Bremerhaven, 27574

Other trials in Germany

Sweden1 site
  • Karolinska Univ Sjukhuset /ID# 135961

    Solna, 17176

Other trials in Sweden

About this study

Official title: An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study

The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.

Read the detailed description

The study will consist of 3 sequential parts:

Part 1: Screening period. The screening period will consist of 3 visits, Visit 1 (V1), Visit 2 ([V2] [optional]) and the Randomization Visit (V3) in which the participant will be assessed to determine eligibility. The duration of the Screening Period can be between 30 to 67 days to accommodate the required procedures, training and collection of diaries, and to allow for stabilization of anti-PD medications and medications to treat NMS. All anti-PD medications and medications to treat NMS are required to be stable for a minimum of 30 days prior to randomization.

Part 2: Treatment period. Those participants randomized to OMT at the end of V3 will remain on their current optimized regimen. The day after randomization will be considered Day 1 of their treatment period and participants will have study visits at the end of Weeks 2, 6, 12, and 26. All participants randomized to the LCIG group should have all anti-PD medications, with the exception of levodopa formulations, tapered off within 14 days after randomization. Optional nasojujunal (NJ) and/or percutaneous endoscopic gastrostomy with a jejunal tube (PEG-J) placement will then occur. After that, the participant may begin initiation and titration of LCIG infusion to be adjusted to obtain the optimal clinical response. The day of initial NJ or PEG-J placement will be considered Day 1 for participants in the LCIG group. Study visits happen at the end of Weeks 2, 6, 12, and 26.

Part 3: Extension/Transition Period. Eligible participants who complete the 26 week study may continue into the Extension Period of the study. Participants in the LCIG arm will have study drug dispensation every 4 weeks and will have study visits every 6 months. Participants from the OMT arm will undergo the NJ (optional) and PEG-J procedures, titration, plus have visits at 2 weeks, 6 weeks, 3 months and 6 months post NJ or PEG-J. Participants will then continue to receive study drug every 4 weeks and will have study visits every 6 months until Duodopa is commercially available. Transition to a Post-Trial Access protocol will be possible if Duodopa does not become commercially available in a location.

Being tested
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Keywords
levodopa-carbidopa intestinal gel, levodopa, carbidopa, Advanced Parkinson's Disease, Non-Motor Symptom Scale NMSS, Parkinson's Disease Sleep Scale PDSS-2, efficacy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Optimized Medical TreatmentDrug

    Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.

  • Levodopa-Carbidopa Intestinal GelDrug

    Also called ABT-SLV187, Duodopa, LCIG

  • Nasojejunal (NJ) tubeDevice

    optional prior to PEG-J placement

  • Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tubeDevice

Study groups in NCT02549092
Study groupRoleWhat they receive
Optimized Medical Treatment (OMT)Active comparatorParticipants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG.
Receives: Drug: Optimized Medical Treatment; Drug: Levodopa-Carbidopa Intestinal Gel; Device: Nasojejunal (NJ) tube; Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Levodopa-Carbidopa Intestinal Gel (LCIG)ExperimentalParticipants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG.
Receives: Drug: Levodopa-Carbidopa Intestinal Gel; Device: Nasojejunal (NJ) tube; Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to Week 26 in the NMSS Total Score

    The NMSS consists of 30 questions in 9 domains (cardiovascular/falls, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, GI tract, urinary, sexual function, miscellaneous). Score of each question is calculated by multiplying severity*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Total score is the sum of 9 domains, and ranges from 0 to 360, with a lower value indicating a more desirable outcome. Repeated-measure analysis.

    Measured: Baseline, Week 26

  2. Change From Baseline to Week 26 in the Modified PDSS-2 Total Score

    The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.

    Measured: Baseline, Week 26

Secondary outcomes (10)
  1. Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score

    The PDQ-8 is a disease-specific instrument designed to measure aspects of health relevant to PD. Eight questions including the mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort are assessed on a 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Summary index score is the sum of each question divided by 32 and multiplied by 100. Scores range from 0 to 100 with lower values desirable.

    Measured: Baseline, Week 26

  2. Clinical Global Impression of Change (CGI-C) Final Score

    CGI-C score is a clinician's impression of a subject's change in status on a 7-point scale (1 = very much improved, 2 = much improved, 3 = minimally Improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse). Scores range from 1 to 7, with lower score desirable.

    Measured: End of Treatment Period (up to Week 26)

  3. Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score

    UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part II scores range from 0 to 52 with lower value desirable.

    Measured: Baseline, Week 26

  4. Change From Baseline to Week 26 in the NMSS Domain Scores

    The NMSS consists of 30 questions in 9 domains. Score of each question is calculated by multiplying severity*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Cardiovascular/falls scores range from 0 - 24 with lower value desirable. Sleep/fatigue scores range from 0 - 48 with lower value desirable. Mood/cognition scores range from 0 - 72 with lower value desirable. Perceptual problems/hallucinations scores range from 0 - 36 with lower value desirable. Attention/memory scores range from 0 - 36 with lower value desirable. Gastrointestinal tract scores range from 0 - 36 with lower value desirable. Urinary scores range from 0 - 36 with lower value desirable. Sexual function scores range from 0 - 24 with lower value desirable. Miscellaneous scores range from 0 - 48 with lower value desirable. Repeated-measure analysis.

    Measured: Baseline, Week 26

  5. Change From Baseline to Week 26 in the Modified PDSS-2 Domain Scores

    The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.

    Measured: Baseline, Week 26

  6. Change From Baseline at Week 26 in UPDRS Parts I, III, and IV Score

    UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part I is the sum of Questions 1 - 4; scores range from 0 to 16 with lower value desirable. Part III is the sum of Questions 18 - 31 (Questions 20 - 26 apply to multiple body parts, resulting in 27 answers total); scores range from 0 to 108 with lower value desirable. Part IV is the sum of Questions 32 - 42; scores range from 0 to 23 with lower value desirable.

    Measured: Baseline, Week 26

  7. Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score

    PAS is a 12-item scale developed specifically to measure severity in anxiety in Parkinson's disease for the following items: Feeling anxious or nervous; Feeling tense or stressed; Being unable to relax; Excessive worrying about everyday matters; Fear of something bad, or even the worst, happening; Panic or intense fear; Shortness of breath; Heart palpitations or heart beating fast; Fear of losing control; Social situations; Public settings; Specific objects or situations. Severity for each item is rated as: 0, Never; 1 Rarely; 2, Sometimes; 3, Often; 4, Nearly always. Total score is the sum of the12 item scores, with a range of 0 to 48; a lower value is desirable.

    Measured: Baseline, Week 26

  8. Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score

    The GDS-15 is a short, self-report reliable and valid screening instrument for depression in the elderly of 15 yes/no questions: 1) Satisfied with life 2) Dropped many activities and interests 3) Life is empty 4) Often get bored 5) In good spirits most of the time 6) Afraid that something bad is going to happen 7) Feel happy most of the time 8) Often feel helpless 9) Prefer to stay at home, rather than going out and doing things 10) Feel that have more problems with memory than most 11) Think it is wonderful to be alive now 12) Feel worthless 13) Feel full of energy 14) Situation is hopeless 15) Most subjects are better off. Answers of 'yes' to questions 2, 3, 4, 6, 8, 9, 10, 12, 14, 15 are scored 1 point. Answers of 'no' to questions 1, 5, 7, 11, 13 are scored

    1 point. The 15 items are summed and scores range from 0 - 15 with lower value desirable.

    Measured: Baseline, Week 26

  9. Change From Baseline at Week 26 in King's PD Pain Scale (KPPS) Score

    The KPPS score is a clinical PD-specific pain scale of 14 items addressing the following 7 domains: musculoskeletal pain, chronic pain, fluctuation-related pain, nocturnal pain, orofacial pain, neuropathic pain, radicular pain. Each domain item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 - 12 (with lower value desirable), the sum of the 14 items gives the total score with a range from 0 to 168 with lower value desirable.

    Measured: Baseline, Week 26

  10. Patient Global Impression of Change (PGIC) Final Score

    The PGIC is a 7-point response scale. The participant was asked by the Investigator or qualified designee to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. PGIC score ranges from 1 to 7 with lower score desirable.

    Measured: End of Treatment Period (up to Week 26)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2015 (estimated)
  2. Study start26 Oct 2015
  3. Primary completion14 May 2020
  4. Study completion18 Nov 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
89 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02549092
Sponsor's protocol ID
M12-927
Other IDs
2014-004865-26, 2014
Status last verified
Nov 2023
First submitted
11 Sep 2015
Last updated
28 Nov 2023
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel and Nasojejunal (NJ) tube in people with Advanced Parkinson's Disease, run by AbbVie at 38 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 38 sites in Spain, United States, Italy, Australia, Canada and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Jun 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Week 26 in the NMSS Total Score (time frame: Baseline, Week 26). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in